Table 5 Clinical trials-thalidomide (Transplant Eligible)
From: Thalidomide and its analogues in the treatment of Multiple Myeloma
Author | Regimen(s) | Type of clinical trial | No. of pts | Best responses (>PR) | CR, nCR, VGPR | PFS/TTP/OS (months) | Reference |
|---|---|---|---|---|---|---|---|
Rajkumar et al | TD vs. D | Phase III | 470 | 63% VS. 46% | CR+VGPR:44% vs. 16% | TTP:22.6 vs. 6.4 | J Clin Oncol 2008 |
Lockhorst et al | TAD vs. VAD | Phase III | 402 | 72% VS. 54% | NR | NR | Haematologica 2008 |
Cavo et al | VTD vs. TD | Phase III | 187 | 93% VS. 79% | NR | NR | ASH 2007 |
Barlogie et al | VTD-PACE | Phase II | 303 | 99% | nCR:83% (2 yr) CR: 56% (2 yr) | EFS:84% (2 yr) OS: 86% (2 yr) | B J Hematol 2007 |